Spyre Therapeutics (SYRE) Citigroup’s Biopharma Back to School Summit 2026 summary

Pipeline progress and strategy

• Focus on developing best-in-class monotherapies and optimized antibody combinations for autoimmune diseases, with the most advanced work in inflammatory bowel disease (IBD).

• Recent data show lead assets are at least as effective as current best-in-class molecules, with some showing potential to surpass first-generation products.

• Combination therapies are being tested head-to-head, with early evidence suggesting additive efficacy and strong safety profiles.

• The goal is to exceed current standards of care by at least 10% in clinical remission rates, a benchmark informed by historical data and physician surveys.

• Ongoing SKYLINE study is designed to demonstrate both monotherapy and combination efficacy, with pivotal readouts expected in 2027.

Competitive landscape and differentiation

• Co-formulation approach enables stable, high-concentration antibody combinations, differentiating from competitors using mixed modalities or less compatible assets.

• Regulatory strategy leverages precedent for non-placebo-controlled phase III trials, aiming for efficient development and faster enrollment.

• Products are positioned to be priced similarly to branded drugs, with convenience and efficacy as key differentiators.

• Market dynamics in IBD favor products that deliver superior efficacy without safety trade-offs, with potential for multiple top-tier products.

Expansion beyond IBD

• TL1A asset is being evaluated in rheumatic diseases (RA, PsA, axSpA) and dermatology (HS), with decisions on monotherapy vs. combination advancement based on upcoming data.

• RA results showed activity but not enough for phase III monotherapy; combinations may be more promising in PsA, axSpA, and HS.

• Combination trials in HS will use HiSCR75 as the primary endpoint, aiming to outperform current standards like Bimzelx.

• Proprietary long-acting IL-17 asset (SPY007) is in development for future combination strategies.